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Systemic administration of the potent vasodilating peptide
adrenomedullin reduces cardiac and renal fibrosis in
hypertensive animals. Here, we investigated the effects
of kidney-specific adrenomedullin gene delivery in
normotensive rats after unilateral ureteral obstruction,
an established model of renal tubulointerstitial fibrosis.
Overexpression of exogenous adrenomedullin in the renal
interstitium following ureteral obstruction significantly
prevented fibrosis and proliferation of tubular and interstitial
cells. In this model, there is upregulation of connective tissue
growth factor (CTGF) mRNA expression and extracellular
signal-regulated kinase (ERK) phosphorylation, and
adrenomedullin overexpression suppressed both of these
activities without altering the blood pressure. In NRK-49F
renal fibroblasts, adrenomedullin reduced transforming
growth factor-b-induced CTGF and fibronectin mRNA
upregulation through the cyclic AMP/protein kinase A
signaling pathway, and suppressed ERK phosphorylation and
cell proliferation. In the kidneys with an obstructed ureter,
adrenomedullin receptor gene expression was upregulated
along with cyclic AMP production in kidney slices. The
latter effect was partially blocked by a neutralizing
antibody to adrenomedullin, indicating that an endogenous
peptide-receptor system was activated. Our results show
that overexpression of exogenous adrenomedullin in the
ureteral-obstructed kidney prevents tubulointerstitial fibrosis
and cell proliferation through the cyclic AMP-mediated
decrease of CTGF induction and ERK phosphorylation.
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Tubulointerstitial fibrosis is a common feature of progressive
renal injury and predicts the long-term outcome of renal
function.1 Among proposed mechanisms by which interstitial
fibrosis progresses, transforming growth factor-b (TGFB1)
plays a central role in the pathogenesis.2–4 TGFB1 promotes
the accumulation of extracellular matrix, through the enhan-
ced synthesis of extracellular matrix proteins, such as fibro-
nectin (FN1), and the inhibition of their degradation.2 We
have revealed that connective tissue growth factor (CTGF) is
an important factor that mediates profibrotic action of
TGFB1 in renal fibroblasts and in unilateral ureteral obstruc-
tion (UUO), an established model of obstructive nephro-
pathy.5,6 Introduction of Ctgf antisense oligonucleotide in
the renal interstitium markedly suppresses renal fibrosis,
but does not inhibit Tgfb1 induction and cell proliferation
in UUO.6
Adrenomedullin (ADM), a potent vasorelaxing and natri-
uretic peptide,7 is expressed in renal glomeruli and tubules.8,9
ADM exerts its actions by stimulating cyclic AMP (cAMP)
production and by nitric oxide release in target tissues.10–12 In
humans, its receptor is composed of calcitonin receptor-like
receptor (CRLR or CALCRL) and a family of receptor-
activity-modifying proteins (RAMPs 1–3). RAMP2/CALCRL
and RAMP3/CALCRL constitute ADM receptors, whereas
RAMP1/CALCRL generates calcitonin gene-related protein
(CGRP or CALCA) receptor.13 We have reported that Ramp1,
Ramp2, and Calcrl mRNAs are markedly upregulated after
UUO in rats, and proposed that the ADM–RAMP system
may modulate the process of tubulointerstitial fibrosis.14
We and others have shown that ADM may either stimulate
or inhibit cell proliferation, depending on the cell types.
ADM has a proliferative action on 3T3 fibroblasts15 and
vascular smooth muscle cells,16 but has an antiproliferative
action on endothelial and mesangial cells,10,17 and cardiac
fibroblasts.18 Systemic administration of ADM, in many
cases, potently reduces blood pressure and exerts protective
effects against cardiac and renal injury.19–21 Heterozygotic
Adm-deficient mice are predisposed to suffering from fibrotic
changes in the cardiovascular system and in the kidney,
indicating that endogenous ADM possesses organ protective
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effects.22–25 Whether local and direct action of ADM in the
kidney is sufficient to prevent tubulointerstitial fibrosis and
whether endogenous ADM–ADM receptor system is activated
in obstructive nephropathy remains to be elucidated. In
the present study, we investigated the effects of ADM over-
expression in renal interstitium upon UUO. Furthermore, we
examined the signaling pathway of ADM in the context of
cAMP/protein kinase A (PKA), extracellular signal-regulated
kinase (ERK or MAPK1/MAPK3), and also CTGF, which we
have been proposing as a crucial profibrotic molecule acting
downsteam of TGFB1 in obstructive nephropathy.6 Finally,
by in situ mRNA hybridization, we investigated the spatial
regulation of ADM–ADM receptor system in UUO.
RESULTS
Renal fibrosis induced by UUO is prevented by exogenous
expression of ADM
To investigate whether exogenous expression of ADM locally
in the kidney ameliorates renal fibrosis induced by UUO,
AxAM, an adenovirus encoding human ADM gene, was
transferred into rat kidney via renal vein using hydrody-
namics-based gene transfer technique.6 Using control AxLacZ
adenovirus injection, successful gene transfer was verified
by positive X-gal staining specifically in interstitial cells of
the obstructed kidney, and by the absence of expression in
the other side of the kidney, liver, spleen, lung, and heart
(Figure 1).6,26 On day 6 after ureter ligation, exogenous
human ADM mRNA expression was detected in AxAM-
infected kidney (Figures 2 and 3). In situ hybridization
revealed that human mRNA was indeed expressed predomi-
nantly in the interstitium, and expression in tubules was
little, if any (Figure 2). In contrast, endogenous rat Adm was
expressed in glomeruli and distal nephrons (presumably
collecting ducts). UUO caused upregulation of rat Adm gene
expression in inner medullary collecting ducts, but expres-
sion pattern in other parts of the kidney did not seem to be
altered. These changes were reflected by slight elevation of rat
Adm expression levels in the whole kidney (1.2-fold, but not
significantly; Figure 3). Gene expression of Tgfb1, the key
molecule involved in tissue fibrosis, was upregulated after
UUO by 3.4-fold, and gene transfer of AxLacZ or AxAM did
not affect the expression level. Gene expression of Ctgf, the
critical factor that mediates profibrotic activity of TGFB1 in
UUO,5,6 was elevated in the obstructed kidney by 1.6-fold as
compared with the sham-operated kidney. Introduction of
AxAM into the kidney markedly inhibited Ctgf mRNA up-
regulation (by 75±8%) compared with control AxLacZ
adenovirus-treated obstructed kidney. Furthermore, gene
expression of an extracellular matrix protein fibronectin
(FN1) was upregulated in the obstructed kidney (4.2-fold
of sham operation), and was significantly attenuated (by
81±10%) with the transfer of AxAM. Immunohistochemical
analysis revealed that FN1-expressing area was increased
by 3.5-fold in UUO and was remarkably decreased in
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Figure 1 | Gene transfer into the rat kidney by hydrodynamics-
based retrograde gene transfer via left renal vein. (a) X-gal
staining (in blue) of the left kidney section at 6 days after
transfection with AxLacZ reporter adenovirus. Arrows indicate the
outer surfaces (basement membranes) of tubules. Original
magnification  200. (b) Expression of LacZ mRNA in various
tissues analyzed by northern blotting.
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Figure 2 | Distribution of endogenous Adm and exogenous ADM in the rat kidney undergoing UUO. (a–f) In situ mRNA hybridization of
the kidney on day 6 after ureter ligation. Gene expression of endogenous rat Adm (in dark blue staining, rAM) was detected in distal nephrons
(a, black arrows) and glomeruli (b, red arrows) in sham-operated kidney, and was upregulated in inner medullary collecting ducts in UUO
kidney (c, black arrows). By clear contrast, exogenous human ADM (hAM) was expressed in the interstitium of ADM-encoding adenovirus-treated
obstructed kidney (e; f, blue arrows), but not in noninfected UUO kidney (d). Original magnification:  100 (d, e),  200 (a, c), and  400 (b, f).
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AxAM-treated kidney (by 67± 9%). Furthermore, fibrosis
score determined by Masson’s trichrome staining was also
elevated in AxLacZ-treated obstructed kidney compared with
sham, and was significantly reduced in AxAM-treated kidney
(the scores were 3.2±0.4 for AxLacZ, 1.1±0.1 for AxAM, and
0.1±0.1 for sham). Urinary volume and systolic blood pressure
measured by the tail-cuff method were not changed signifi-
cantly after 6 days of UUO and by AxAM treatment (Figure 4).
These observations show that exogenous ADM expressed in the
renal interstitium inhibited renal fibrosis in UUO.
Cell proliferation after UUO is suppressed by exogenous
expression of ADM
Because cellular proliferation of tubular and interstitial
cells is one of the hallmarks of obstructive nephropathy, we
carried out Western blot analyses for proliferating cell nuclear
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Figure 3 | Effects of ADM gene transfer in the rat kidney undergoing UUO. (a–d) Northern blot analysis of the kidney on day 6
after ureter ligation. S, sham-operated kidney; U, vehicle-treated ureter-ligated kidney; L, AxLacZ-treated obstructed kidney; AM, AxAM
(ADM-encoding adenovirus)-treated obstructed kidney. The relative mRNA levels of Tgfb1 (TGF-b), Ctgf (CTGF), and Fn1 (FN) were
normalized with 28S ribosomal RNA. rAM, rat Adm; hAM, human ADM. Mean levels of the sham-operated kidney from control rats were
determined as 1.0 arbitrary unit. (e–h, m) Immunofluorescence staining of FN1 (FN) using fluorescein-conjugated antibody and quantified
relative FN1þ areas. (i–l, n) Fibrotic areas determined by Masson’s trichrome staining (shown in blue) and semiquantitative scores of
tubulointerstitial fibrosis. Original magnification  200. *Po0.05; **Po0.01; NS, not significant; n¼ 5 per each group.
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antigen (PCNA) and phosphorylated MAPK1/MAPK3, and
immunostaining for PCNA. As shown in Figure 5, PCNA
expression in the whole kidney was significantly increased
after 6 days of ureter ligation, but upregulation of PCNA
expression was significantly decreased in AxAM-treated
kidney as compared with control AxLacZ-treated obstructed
kidney (4.5- vs 9.6-fold of sham operation, respectively).
Immunohistochemical study also indicated that the number
of PCNAþ-proliferating cells in the obstructed kidney was
increased both in the tubules and in the interstitium, and was
decreased with ADM treatment. Cellular proliferation (Figure
5h and i) and extent of interstitial fibrosis (Figure 3m and n)
were proportional to kidney weight/body weight ratio of the
obstructed kidney (Figure 4c). Activation of MAPK1/MAPK3
plays an important role in tubular and interstitial cell
proliferation.27 The level of phosphorylated MAPK1/MAPK3
in whole kidney of AxLacZ-treated UUO rats was signifi-
cantly increased (by 7.0-fold), compared with that in sham-
operated kidney (Figure 5). AxAM treatment significantly
suppressed MAPK1/MAPK3 phosphorylation in UUO (by
69±13%). These findings indicate that renal cell prolifera-
tion during UUO was inhibited by ADM treatment, which
may be due to reduced MAPK1/MAPK3 phosphorylation.
ADM inhibits TGFB1-induced Ctgf and Fn1 upregulation
through the cAMP/PKA signaling pathway
To address the molecular mechanism of ADM-mediated
kidney protection in UUO, we examined direct actions
of ADM on cultured NRK-49F normal rat renal fibroblasts.
We investigated the effects of ADM on TGFB1-induced
expression of CTGF and its downstream molecule FN1, both
of which are critical mediators of tissue fibrosis.5,6 Ctgf
expression was strongly increased by TGFB1 in fibroblasts,
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Figure 4 | Effects of ADM gene transfection on blood pressure,
urinary volume, and kidney weight following renal
obstruction in rats. (a) Systolic blood pressure. (b) Urinary
volume. (c) Left kidney/body weight ratio. S, sham; U, vehicle
treated UUO; L, AxLacZ-treated UUO; AM, AxAM-treated UUO.
Mean±s.e.m. n¼ 5; **Po0.01 vs each basal level; wPo0.05 vs
U and L at day 6.
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Figure 5 | PCNA expression and ERK (MAPK1/MAPK3)
phosphorylation in the kidney of obstructive nephropathy.
(a) Western blots of PCNA, b-actin, and phosphorylated and total
MAPK1/MAPK3 (p-ERK and t-ERK) at day 6 after ureteral
obstruction. Equal amounts of protein (40 mg per lane) from
the whole kidney were separated by electrophoresis. S,
Sham-operated kidney; U, vehicle-treated obstructed kidney;
L and lacZ, AxLacZ-treated obstructed kidney; AM, AxAM-treated
obstructed kidney. (b, c) The relative levels of PCNA/b-actin and
p-ERK/t-ERK measured with densitometer. (d–g) Immunohisto-
chemistry for PCNA (stained in brown) in the obstructed kidney.
Original magnification  400. All the nuclei were further
visualized with hematoxylin counterstaining for quantification
(not shown). (h, i) The ratio of PCNAþ cells in renal tubular
and interstitial cells. **Po0.01, NS, not significant; n ¼ 5.
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and pretreatment with ADM dose dependently inhibited
TGFB1-induced Ctgf mRNA upregulation (Figure 6). Because
cAMP and cyclic GMP (cGMP) are major intracellular signal-
ing molecules for ADM action, we examined whether they
can substitute for ADM as to suppression of Ctgf induc-
tion. Membrane-permeable analogs of cAMP and cGMP
(8-bromo-cAMP and 8-bromo-cGMP) both effectively
abolished the upregulation of Ctgf gene expression. Essen-
tially, similar results were obtained on Fn1 gene expression.
These findings raised the possibility that ADM inhibits TGFB1-
induced Ctgf and Fn1 upregulation through cAMP, cGMP,
or both. Therefore, we examined which of cAMP and cGMP is
the predominant mediator of the antifibrotic action of ADM.
Pretreatment with PKA inhibitors, Rp-cAMP (adenosine 30,50-
cyclic monophosphorothioate) and myristoylated PKA inhi-
bitor amide 14–22, canceled ADM-induced inhibition of Ctgf
and Fn1 upregulation (Figure 6). By contrast, protein kinase G
inhibitor Rp-cGMP (guanosine 30,50-cyclic monophosphoro-
thioate) and phosphatidylinositol 3-kinase inhibitor LY294002
had no significant effects. In control experiments, both PKA
inhibitors reversed inhibitory effects of cAMP itself on TGFB1-
induced Ctgf and Fn1 mRNA upregulation. Finally, ADM
stimulated intracellular cAMP production in NRK-49F cells
(Figure 7a). These findings show that the antifibrotic effects of
ADM in cultured renal fibroblasts were mediated mainly
through the cAMP/PKA cascade.
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Figure 6 | Antifibrotic effects of ADM upon NRK-49F normal rat kidney fibroblasts. (a) Northern blot analysis of TGFB1 (3 ng ml1)-
induced upregulation of Ctgf and Fn1 gene expression, and suppression by ADM (AM, final 109–106 M) and by 8-bromo-cAMP and
8-bromo-cGMP (AMP and GMP, 1 mM each). Veh, vehicle. (b) Effects of protein kinase inhibitors upon the antifibrotic actions of ADM
(AM, 1 mM). Rp-cAMP (RpAM, 10mM) and myristoylated protein kinase A inhibitor amide 14–22 (PKI, 0.5mM) are inhibitors for PKA; RpGM,
protein kinase G inhibitor Rp-cGMP (10 mM); LY, phosphatidylinositol 3-kinase inhibitor LY29400 (10 mM). (c) cAMP/PKA-dependent inhibition
of TGFB1-induced fibrotic changes. *Po0.05, **Po0.01 vs TGFB1 alone; wPo0.05 vs TGFB1þADM/cAMP, n¼ 6.
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Figure 7 | Antiproliferative effects of ADM upon NRK-49F cells. (a) ADM (AM, final 1010–107 M)-stimulated increase of cAMP
production. Veh, vehicle. *Po0.05 vs vehicle. (b) Inhibitory effects of ADM upon PDGF-BB (PDGF, 3 ng ml1)-stimulated 3H-thymidine
incorporation. *Po0.05 vs vehicle, wPo0.05 vs PDGF alone, n¼ 6. (c, d) Inhibitory effects of ADM upon MAPK1/MAPK3 phosphorylation.
ADM (AM, 1 mM) and cAMP analog (AMP, 1 mM) significantly inhibited PDGF (3 ng ml1)-induced phosphorylation of MAPK1/MAPK3. p,
phosphorylated; t, total. Equal amounts of protein (40 mg per lane) were subjected to Western blot analysis. *Po0.05 vs PDGF alone, n¼ 4.
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ADM suppresses proliferation and MAPK1/MAPK3
phosphorylation of renal fibroblasts
Adrenomedullin has a proliferative action on 3T3 fibroblasts15
and vascular smooth muscle cells,16 but has an antiprolifera-
tive action on endothelial and mesangial cells.10 We examined
the effects of ADM on renal fibroblast proliferation. ADM
inhibited platelet-derived growth factor (PDGF)-BB-induced
DNA synthesis in a dose-dependent fashion (Figure 7). Next,
we examined the effects of ADM on MAPK1/MAPK3
phosphorylation, as MAPK1/MAPK3 phosphorylation plays
a key role in the induction of interstitial cell proliferation.27
Preincubation with ADM or a membrane-permeable cAMP
analog significantly inhibited PDGF-induced MAPK1/
MAPK3 phosphorylation (Figure 7). These results indicate
that ADM inhibited MAPK1/MAPK3 phosphorylation and
renal fibroblast proliferation.
cAMP production is augmented in UUO kidney, partially by
endogenous ADM
In this study, we have demonstrated that exogenous ADM
inhibits Ctgf and Fn1 upregulation and cell proliferation in
UUO kidney and in cultured renal fibroblasts, and that
cAMP plays a crucial role in these ADM actions. Using cAMP
as a reporter, we investigated whether the endogenous
ADM–ADM receptor system is activated in UUO. Basal
cAMP production of renal tissue slices from whole kidney
was increased by 2.4-fold in UUO compared with control
(Figure 8). This was also true when the medulla, cortex, or
glomeruli was examined separately. Addition of ADM
increased cAMP production in the medulla and glomeruli
from control and UUO rats, indicating the presence of
active ADM receptors. To evaluate the contribution of
endogenous ADM in enhanced rate of cAMP production in
UUO kidney, ADM-neutralizing antibody was added to renal
tissue slices. Basal cAMP production in control kidney
was not affected significantly by ADM-neutralizing antibody
(Figure 8). In contrast, the antibody partially inhibited cAMP
elevation in whole kidney, medulla, cortex, and glomeruli
from UUO rats. As a control, control ascites gave no effects.
These findings indicate that the endogenous ADM–ADM
receptor system was activated in UUO kidney.
Transient coexpression of Calcrl (CRLR) and Ramp2 or Ramp3
generate ADM receptor, and Calcrl and Ramp1 generate
CALCA (CGRP) receptor
In humans and mice, functional reconstitution of RAMPs 1–3
and CALCRL as ADM or CALCA receptor has been
reported.13,28–30 To clarify the rat ADM receptor selectivity,
we made expression vectors for rat Ramp’s and Calcrl and
transfected them into COS-7 cells. As shown in Figure 9,
when Ramp2 or Ramp3 was co-transfected with Calcrl, ADM
markedly increased cAMP production, but when Ramp1 and
Calcrl was co-transfected, ADM induced little cAMP
production. In contrast, only when Ramp1 was co-transfected
with Calcrl, CALCA markedly increased cAMP production
(Figure 9). These results indicate that similarly to human
counterparts, transient coexpression of rat Calcrl and Ramp2
or Ramp3 generated the receptors specific to ADM, and that
Calcrl and Ramp1 generated the CALCA receptor.
Ramp2 and Ramp1 are upregulated in renal medulla, cortex,
and glomeruli after UUO
To further characterize the role of RAMPs 1–3 in UUO, we
analyzed their renal distribution and the change of expres-
sion. Northern blot analyses revealed that Ramp1 was mainly
upregulated in medulla and cortex, Ramp2 in medulla,
cortex, and glomeruli at 6 days after UUO, whereas Ramp3
was unchanged (Figure 10). Through all these in vivo and
in vitro experiments, it is suggested that upregulation of
Ramp2 expression activated the ADM–ADM receptor system
in UUO kidney.
Ramp1 is expressed in all nephron segments, upregulated
evenly, and newly induced in interstitium after UUO
Finally, we investigated renal distribution of Ramp2 gene
expression before and after UUO (Figure 11). In situ
hybridization revealed that Ramp2 was expressed in virtually
all nephron segments including glomeruli in sham-operated
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wPo0.05, zPo0.01 vs basal (ADM-untreated conditions) of control
(non-UUO kidney); *Po0.05, **Po0.01, significant changes by
ADM (a) or by neutralizing ADM antibody treatment (b); n¼ 6.
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kidney. Especially, distal nephrons (such as thick ascending
limbs of Henle and collecting ducts) expressed Ramp2 abun-
dantly. After UUO, Ramp2 gene expression was enhanced
evenly in nephron segments. At the same time, de novo
expression was induced in interstitium adjacent to dilated
distal nephrons. These findings suggest that renal interstitium
was an important target of endogenous and exogenous ADM
in the present study.
DISCUSSION
In the present study, we locally overexpressed exogenous
ADM predominantly in the renal interstitial cells in obstruc-
ted nephropathy by injecting ADM-encoding adenovirus via
renal vein, and revealed the protective action of ADM, which
was characterized with suppression of interstitial fibrosis and
of cellular proliferation. Administration of ADM adenovirus
also caused downregulation of CTGF, FN, PCNA, and
phosphorylation of MAPK1/MAPK3 in the kidney. Unlike
systemic delivery of the Adm gene19,20 or administration of
ADM21 in previous reports, we did not observe blood
pressure reduction in our model, highlighting the importance
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obstructed kidney at day 6. The expression levels in the whole kidney from control (sham operated) rats were defined as 1.0 arbitrary unit.
WK or W, whole kidney; Med or M, medulla; Cx or C, cortex; Gl or G, glomerulus. *Po0.05, **Po0.01 vs control. n¼ 5.
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Figure 11 | Localization and changes of Ramp2 mRNA expression in the kidney after UUO. (a, b) In sham-operated kidney, Ramp2 was
expressed in all nephron segments, such as glomeruli, proximal tubules (P), and distal nephrons (black arrows). (c) Control sense probe gave
no signals in UUO kidney. (d–f) In UUO kidney, Ramp2 was upregulated evenly in nephrons, and was newly induced in interstitium
(red arrows) adjacent to dilated distal nephrons (D). Original magnification:  40 (a, c, d) and  200 (b, e, f).
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of direct renal actions of ADM in modulating the patho-
physiology of UUO.
In the process of renal interstitial fibrosis, renal fibroblasts
play a key role by their involvement in the proliferation,
migration, and synthesis of growth factors and matrix
proteins.31–33 ADM stimulates not only cAMP production
but also calcium mobilization in cultured endothelial cells.
The latter effects result in an increased nitric oxide produc-
tion to enhance cGMP accumulation in the vasculature,
thereby contributing to vasodilatory effects of ADM in
concert with increased cAMP production.11,12 In this study,
we showed that ADM significantly suppressed TGFB1-
induced upregulation of Ctgf and Fn1 expression in NRK-
49F renal fibroblasts. ADM as well as membrane-permeable
analogs of cAMP and cGMP, both of which are intracellular
signaling molecules of ADM, effectively abolished the
upregulation of Ctgf and Fn1 mRNA. Pretreatment with
PKA inhibitor reversed this suppression, but neither protein
kinase G inhibitor nor phosphatidylinositol 3-kinase inhi-
bitor affected the response, demonstrating the critical role of
the cAMP/PKA pathway in fibrogenesis of these cells.
Sustained activation of MAPK1/MAPK3 in renal tubular
and interstitial cells in UUO provides a possible mechanism
of the proliferative response against interstitial injury.27 We
and others have reported potent inhibitory effects of ADM
on mesangial cell proliferation,10,34–37 but little is known
about the antiproliferative action of ADM on tubulointer-
stitial cells in vivo and in vitro. The present study revealed
that the tubulointerstitial proliferation was attenuated in
the kidney overexpressing ADM gene with the inhibition
of MAPK1/MAPK3 phosphorylation.24 Furthermore, ADM
decreased PDGF-induced thymidine incorporation and
MAPK1/MAPK3 phosphorylation in NRK-49F cells, consis-
tently with a recent work reporting that ADM inhibited basal
and EGF (epidermal growth factor)-stimulated proliferation
in these cells.38 Because interstitial volume expansion in
obstructed kidney has been attributed to fibroblast differ-
entiation/proliferation and extracellular matrix deposition,39
the suppressive effects of ADM on the increasing renal mass
of the ligated kidney are likely the results of antiproliferative
and antifibrotic effects of ADM on renal fibroblasts. Interes-
tingly, suppression of CTGF activity in UUO by introduction
of antisense oligonucleotide through renal vein only inhi-
bited fibrotic changes but did not affect renal cell prolifera-
tion,6 although overexpression of ADM via a similar route in
this study reduced both tubulointerstitial fibrosis and
proliferation. These findings highlight the potentially distinct
effects of the future strategy to treat fibrosis-associated renal
diseases either by CTGF blockade or by ADM administration.
We and others have shown that ADM possesses a potent
inhibitory activity against oxidative stress, which may also
play a role in its antifibrotic effects described in the present
study.22,23,40,41
In the UUO kidney, cAMP production rate was enhanced,
which was partially blocked with ADM-neutralizing anti-
body. We show here that Ramp2 expression is upregulated in
the obstructed kidney, and that overexpression of Ramp2 and
Calcrl reconstitutes a functional rat ADM receptor. There-
fore, we propose that upregulation of Ramp2 expression plays
an important role in the activation of the endogenous
ADM–ADM receptor system in UUO, and this may augment
the protective effects of exogenous ADM.
Furthermore, we investigated renal localization of rat
Adm, Ramp2, and human ADM by in situ hybridization.
Exogenous human ADM, introduced by retrograde adeno-
virus infection via renal vein, was expressed predominantly
in the interstitium. In a previous report, it was demonstrated
that the gene delivery method used in this study specifically
targets interstitial fibroblasts, and spares endothelial cells and
proximal tubules.26 Despite highly localized expression,
exogenous ADM exerted potent protective effects upon both
tubular and interstitial cells. This may be explained by
possibilities that the gene delivery enhanced secretion of
protective factors (including ADM) and, at the same time,
suppressed release of deteriorating factors (such as CTGF)
from renal interstitium, and that these soluble factors acted
in paracrine manners. We also found that, in UUO kidneys,
Ramp2 expression was upregulated along all nephron
segments and was also induced in the interstitium. Over-
expression of exogenous ADM in interstitium did not reflect
a physiologic response to UUO (because we did not find
upregulation of endogenous rat Adm in the interstitium), but
turned out to be an excellent strategy to carry out gene
therapy.
In summary, we demonstrate here that adenovirus-
mediated ADM gene delivery into the kidney ameliorates
the histologic alterations caused by UUO. The results also
suggest that the renoprotective effects of ADM in tubuloin-
terstitial proliferation and fibrosis are not due to systemic
blood pressure reduction, but due to cAMP-dependent CTGF
suppression and inhibition of MAPK1/MAPK3 phosphory-
lation. These findings indicate that ADM may offer a new
therapeutic strategy to prevent renal fibrosis in obstructive
nephropathy and perhaps in other chronic nephropathies
leading to tubulointerstitial fibrosis.
MATERIALS AND METHODS
Materials
Human ADM and CALCA (CGRP) were obtained from Peptide
Institute (Osaka, Japan). 8-Bromo-cAMP and 8-bromo-cGMP were
from Sigma (St Louis, MO, USA), and Rp-cGMP (final 10 mM) was
from Biolog (La Jolla, CA, USA). Rp-cAMP (10 mM), myristoylated
PKA inhibitor amide 14–22, and LY294002 were purchased from
Calbiochem (San Diego, CA, USA).
Construction of recombinant adenovirus
Recombinant adenovirus encoding human ADM cDNA was
synthesized by COS-TPC method42 using Adenovirus Expression
Vector Kit (Takara Shuzo, Otsu, Japan). Briefly, human ADM cDNA
(nucleotides (nt) 124–737) containing the complete coding region of
ADM7 was ligated into cosmid cassette vector pAxCAwt, which
contains the CAG promoter consisting of cytomegalovirus imme-
diate early enhancer and chicken b-actin/rabbit b-globin hybrid
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promoter,43,44 and was co-transfected into 293 cells together with
EcoT221-digested DNA-TPC (from Ad5dlx) to generate replication-
deficient adenovirus AxAM.42
Unilateral ureteral obstruction and in vivo gene transfer
using hydrodynamics-based technique
All animal experiments were conducted in accordance with our
Institutional Guidelines for Animal Research. Viral vectors were
introduced into rat kidney by means of a recently developed
hydrodynamics-based gene transfer technique.6,26 In brief, male
Wistar rats weighing B200 g were anesthetized with pentobarbital,
the left kidney was exposed by midline incision, and the left ureter
was ligated with 4-0 silk at two points.6 The recombinant adenovirus,
AxAM (5 109 PFU dissolved in 750ml of Ringer solution; Sigma) or
AxLacZ (control adenovirus AxCALacZ, a gift from Dr Y Kanegae,
Tokyo University) was then injected into the left renal vein using a
24-gauge SURFLO intravenous catheter (Terumo, Tokyo, Japan) after
clamping the left renal vein. Blood flow was reestablished 10 min
after injection. Rats were killed 6 days after UUO or sham operation.
Histology and immunohistochemistry
For histological analysis, sagittal kidney sections fixed with 4%
buffered paraformaldehyde were embedded in paraffin and 2-mm-
thick sections were stained with Masson’s trichrome.5 The fibrotic
area was measured semiquantitatively45 using a computer-aided
manipulator (KS400; Carl Zeiss Vision, Munich, Germany). Thirty
randomly selected fields were examined by two investigators without
knowledge of the origin of the slides, and graded semiquantitatively
(0–4) according to the area of positive staining (score 0, o5%; 1,
5–25%; 2, 25–50%; 3, 50–75%; and 4, 475%). Then, the mean score
per section was calculated. Immunohistochemistry for PCNA was
performed using mouse anti-PCNA antibody and LSABþ kit
(DAKO Japan, Kyoto, Japan).6 PCNA-positive cells in renal tubules
and in the interstitium were counted separately in 20 high-power
fields. Immunofluorescence study of FN1 was carried out with
mouse anti-FN ED-A antibody (Abcam, Cambridge, UK). Ratio of
positively stained areas was computer analyzed using NIH Image
and expressed as percentages.6
Cell culture, DNA transfection, and proliferation study
COS-7 cells and NRK-49F cells were maintained in DMEM
(Dulbecco’s modified Eagle’s medium; Sigma) containing 10% fetal
calf serum, 100 U ml1 penicillin, and 100 mg ml1 streptomycin.
The cDNA encoding rat Calcrl,46 modified to provide a consensus
Kozak sequence,47 and Ramp cDNAs14 were cloned into pCAGGS/
Neo (a gift from Dr J Miyazaki, Osaka University). Transient
transfection into COS-7 cells was carried out using Effectene
Transfection Reagent (QIAGEN, Santa Clarita, CA, USA). For
TGFB1 stimulation, cells atB90% confluence were made quiescent
in serum-free DMEM supplemented with 10 mg ml1 insulin,
10 mg ml1 transferrin, and 10 ng ml1 selenium (Sigma). After
24 h of serum starvation, cells were treated with protein kinase
inhibitors 30 min before the addition of 1 mM ADM, 1 mM 8-bromo-
cAMP, or 8-bromo-cGMP. One hour later, fibroblasts were
stimulated with 3 ng ml1 of human TGFB1 (R&D Systems,
Minneapolis, MN, USA) and incubated for 48 h, or incubated with
3 ng ml1 of PDGF-BB (Becton Dickinson Labware, Bedford, MA,
USA) for 18 h. For proliferation study, cells were pulsed with 3H-
thymidine for the final 6 h, and the tracer incorporated into the cells
was measured in a liquid scintillation counter.10
Northern blot analysis
Total RNA from the kidney or cultured cells was extracted by
the acid guanidinium thiocyanate–phenol–chloroform method.
Northern blot analysis was performed as described previously.14
32P-labeled cDNA probes for rat Ctgf (nt 1221–1803), Tgfb1
(nt 1142–1546), Fn1 (nt 619–1082),6 Adm (nt 19–591),48 Calcrl
(nt 2001–2668),46 and rat Ramp family14 were prepared by standard
reverse transcription-PCR. The amount of RNA loaded in each lane
was normalized with 28S ribosomal RNA.
cAMP measurement
Basal cAMP production and ADM-stimulated cAMP production in the
cells and tissues were measured by radioimmunoassay.10 In brief,
cultured COS-7 and NRK-49F cells grown to confluence in 24-well
plates were washed twice with serum-free DMEM and preincubated for
20 min at 371C in 400ml DMEM containing 0.1% bovine serum
albumin and 0.5 mM isobutylmethylxanthine (IBMX; Sigma). Human
ADM or CALCA was added to the culture and cells were further
incubated for 30 min at 371C. After incubation, 1 ml of ice-cold ethanol
was added to the culture to disrupt the cells and the mixture was
centrifuged at 15 000 r.p.m. for 10 min at 41C. The supernatant was
vacuum dried and the pellet dissolved in assay buffer was subjected to
RIA (Yamasa, Tokyo, Japan). For rat tissue slice cAMP measurement,
1.5-mm-thick renal tissue slices prepared by a tissue slicer (Medical
Agent, Tokyo, Japan) or isolated glomeruli were incubated in 0.1%
bovine serum albumin/Hank’s balanced salt solution (Sigma) and
0.5 mM IBMX with or without 10mM human ADM for 5 min at 371C
and were homogenized, and the cAMP content was measured. For
neutralization experiment, anti-ADM monoclonal antibody10 or
control mouse ascites was added 10 min before ADM addition.
Western blot analysis
Western blot analysis was performed as described6 using anti-PCNA,
anti-phospho-MAPK1/MAPK3 (ERK1/2), anti-total MAPK1/
MAPK3 (New England Biolabs, Boston, MA, USA), and anti-b-
actin antibodies (Sigma; as an internal control).
In situ mRNA hybridization
To prepare cRNA probes, cDNA fragments encoding rat Adm (nt
3–573),48 rat Ramp2 (nt 103–691),49 and human ADM (nt 124–741)7
were amplified by standard reverse transcription-PCR and ligated
into pGEM-T Easy plasmid vector (Promega, Madison, WI, USA).
Digoxigenin-labeled sense and antisense probes were synthesized
with SP6 and T7 RNA polymerases (Roche Diagnostics, Penzberg,
Germany) after linearizing the plasmids. In situ hybridization was
carried out by an automated application (Ventana Medical Systems,
Tucson, AZ, USA).50 The rat kidneys were fixed in 4% paraformal-
dehyde and embedded in paraffin. Sections of 8-mm thickness were
deparaffinized, fixed, hydrogen chloride treated, and were subjected
to cell conditioning and protease digestion. Hybridization was
performed with antisense or sense probe (10 ng per side) at 601C
for 5 h in RiboHybe hybridization solution (Ventana Medical
Systems). Hybrids were detected with alkaline phosphatase-
conjugated anti-digoxigenin antibody (Roche Diagnostics) and nitro
blue tetrazolium chloride 5-bromo-4-cloro-3-indolyl phosphate
4-toluidinium salt. The sections were counterstained with Fast Red.
Statistical analysis
Data are expressed as the mean±s.e.m. Statistical analysis was
performed using analysis of variance followed by Scheffe’s test.
P-value o0.05 was considered statistically significant.
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